Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange
NCT ID: NCT02095821
Last Updated: 2020-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
2 participants
OBSERVATIONAL
2014-02-28
2019-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
NCT02568696
A Study That Will Look at the Impact of Immunosuppression on Antibody Production in Kidney Transplant Recipients.
NCT00275717
Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
NCT05811468
Blood Biomarkers in Pediatric Kidney Transplant Recipients
NCT05477082
Donor Specific HLA Alloantibodies in Liver Transplantation
NCT02784080
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Humoral rejection, TPE
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* chronic liver disease (Child C)
* therapeutic anticoagulation
* malnutrition (BMI\<17.5)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hannover Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Julius Schmidt
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sascha David, MD
Role: PRINCIPAL_INVESTIGATOR
Medical School Hannover
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hannover Medical School
Hanover, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIB-2110-2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.